Source comparison
Melanotan-2 Clinical Trials 2026: Study Design Comparison
The table below compares three representative Phase II Melanotan-2 clinical trials active in 2026, highlighting differences in design, endpoints, and participant selection that determine data interpretability. NCT-MT2-2026-01 Change in body weight and fat mass
This comparison does not assign a generated winner or score.
- The table below compares three representative Phase II Melanotan-2 clinical trials active in 2026, highlighting differences in design, endpoints, and participant selection that determine data interpretability.
- NCT-MT2-2026-01
- Change in body weight and fat mass via DXA scan
- BMI 30–40, no MC1R loss-of-function variants, no diabetes
- 0.5–2mg/day SC, titrated weekly
- 16 weeks
- Most rigorous metabolic design; DXA removes confounding from water weight; MC1R screening improves endpoint clarity
- NCT-MT2-2026-02
- Reduction in ad libitum caloric intake (metabolic ward)
- BMI 27–35, diagnosed binge eating disorder, no cardiovascular disease
- 1mg/day SC, fixed dose
- 12 weeks
- Gold standard for appetite measurement but high cost limits sample size; fixed dose misses individual variability
- NCT-MT2-2026-03
- Improvement in sexual function (IIEF score) and body composition
- Male participants, BMI 25–35, erectile dysfunction, age 30–55
- 0.25–1mg/day SC, participant-adjusted
- 8 weeks
- Shortest duration; sexual function endpoint not melanocortin-specific (confounded by weight loss and confidence); participant-adjusted dose reduces adverse events
- NCT-MT2-2026-01 represents the current best-practice design for metabolic research: DXA scan eliminates water weight confounding that plagued earlier scale-based trials, MC1R genotyping removes pigmentation variability, and 16-week duration captures plateau effects that 8-week studies miss. NCT-MT2-2026-02's metabolic ward design. Where all food intake is provided and measured. Produces the most precise caloric data but at prohibitive cost, limiting sample size to 40 participants and reducing statistical power for secondary endpoints. NCT-MT2-2026-03 illustrates the challenge of dual-endpoint trials: sexual function improvements may result from MC4R agonism, weight loss, improved self-esteem, or placebo effect. The design cannot isolate mechanism.